Development of Risk Score Model and Decision Tree Algorithm for Predicting Infections With CRKp in Colonized Patients (DETERMINE)

January 12, 2020 updated by: SCARE (Study group for carbapenem resistance)

Development of Risk Score Model and Decision Tree Algorithm for Predicting Bloodstream Infections (BSIs) or Other Invasive Infections With Carbapenem Resistant Klebisella Penumoniae (CRKp) in CRKp Colonized Patients (DETERMINE)

DETERMINE trial is a prospective multicenter multinational cohort study. This study will be carried out to predict the risk of bloodstream infections (BSIs) or other types of invasive infection with carbapenem resistant K.pneumoniae in patients being colonized by CRKp. The results of DETERMINE trial would be quite important to prevent unnecessary coverage of carbapenem resistant Klebsiella pneumoniae in empirical treatment of colonized patients. In this study, both risk score model and decision tree algorithm will be constructed and compared with each other in terms of sensitivity, specificity, positive predictive value and negative predictive value.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

1. Main Objectives:

  1. Building a risk score model and decision tree algorithm with an acceptable certainty for early prediction of BSI or other invasive infections caused by CRKp in CRKp carriers.
  2. Comparison of risk score model and decision tree algorithm in terms of sensitivity and specificity rates, positive predictive and negative predictive values
  3. Evaluation of risk score model and decision tree algorithm in terms of convenience for routine clinical use

2. Hypothesis

2.1 Main hypothesis:

Presence of immunosuppression, invasive devices, gastrointestinal surgery within prior 3 months, multi-site colonization beside stool, older age, diabetes as a comorbidity, admission to ICUs, presence of carbapenemase gene in CRKp that causes colonization, type of carbapenemase (eg. blaOXA-48 and blaKPC ), high SOFA score, high APACHEII score, high ECOG score (>2), short time interval between identification of colonization and development of BSI or other type of invasive infection are independent risk factors for development of subsequent BSI or other invasive infections in CRKp colonized participants

2.2 Secondary hypothesis:

  1. Sensitivity and specificity rates are similar in risk score model and decision tree algorithm.
  2. Positive and negative predictive values are similar in risk score model and decision tree algorithm.
  3. Both risk score model and decision tree algorithm are feasible for usage in our daily practices.

3. Study Design:

Prospective multi-centre multinational study

4. Setting and study period:

Tertiary care hospitals form different parts of the world will be included in DETERMINE trial. Study period is scheduled to be 01.04.2020-01.04.2021 or longer until pre-defined sample size is attained. Each participant will be included only once at the time of first infectious episode (BSI or other type of invasive infections) caused by CRKp or any other bacteria even if more than one infectious episode is reported. Local (primary) investigators will collect microbiological and clinical data of participants and record these data in a standardized electronic case report form. Site investigators will screen all patients who are admitted to ICUs, burn ward, solid and bone marrow transplant units, all patients who are admitted to wards in which an outbreak with CRKp is detected, all patients who share the same room with a patient colonized or infected with CRKp by rectal swab with once a week interval regularly. The participants who have CRKp rectal colonization will be screened by axillary, inguinal and surgical wound screening as well. These patients will be followed for emergence of BSI or other types of invasive infection for 90 days starting from identification of rectal colonization (day 0). Periodic rectal screening with once a week interval will be applied for non-colonized patients during their hospitalization. Carbapenem resistance in Klebsiella pneumonia isolates will be determined according to 2015 CDC criteria.

5. Sample Size:

The sample size can be determined by the number of parameter included in logistic regression model. Ideally, the number of participants that should be involved is calculated by multiplying the number of parameters involved in multivariate logistic regression model with 40. Therefore, the sample size needs to be at least 520 if all hypothesized parameters take place in logistic regression model (Peduzzi P., Concato J., Kemper E., Holford T.R., Feinstein A.R. (1996), A Simulation Study of Number Per Variable In Logistic Regression Analysis, J.Clin.Epidemiology, Vol 12, 1373-1379).

6. Follow-up

The regular assessment of participants will be carried out during hospitalization and after discharge. it will be performed in once a month interval through 90-days follow-up. The participants will be primarily evaluated for occurrence of any type of invasive infection (blood stream or other type of invasive infections). The participants will be warned to apply to our centres until the completion of 90-day follow-up period when symptoms of infection develop (eg fever, chills). Also, participants will be informed to call physicians who are primary investigators of particular centre when they arrive to hospital clinic or emergency department. Primary investigators will evaluate participants and send their culture samples according to clinical necessity. After review of the results of cultures and clinical presentation, the patients will be allocated into one of three different groups constituted by (i) infections with carbapenem resistant Klebsiella pneumonia, (ii) invasive infections with other type of microorganisms and (iii) non-infectious groups. In statistical analysis, cases with bloodstream infection and other types of invasive infection will be grouped and analysed separately. If the participant is discharged before completion of the 90-days, he/she will be contacted in 30-days interval by telephone call to appraise the investigated outcomes.

7. Microbiological Analysis:

Antimicrobial susceptibility tests (AST) will be performed in each centre and not be repeated. Therefore, AST results will be obtained from hospital database. Multiplex PCR will be used for identification of type of carbapenemases among CRKp isolates (both isolates recovered in rectal swab sample and blood or other site cultures). EUCAST breakpoints will be applied for identification of carbapenem resistant Klebsiella pneumonia. Rectal swab processing and identification of CRKp colonization will be performed according to CDC recommendations as follows: Perirectal swabs will be placed into universals containing 5 ml tyriptic soy broth (Oxoid, UK) with an ertapenem 10 ug disk and send to the reference centre in each country for overnight incubation at 37 °C. The broth cultures are then inoculated onto MacConkey agar (Oxoid, UK), and lactose-fermenting colonies are identified with an automatized system such as API20E or Vitek-2 etc. and confirmed by MALDI-TOF Biotyper CA system (Bruker, Daltonics, Bremen, Germany). Carbapenem resistance will be determined phenotypically with ertapenem E-test (bioMerieux, France) and the isolates with a MIC value of > 0.5 mg/L are reported as CRKp.

In BSIs or other invasive infections, only the first CRKp isolate of each patient will be included. Multiplex PCR (Polymerase chain reaction) will be applied for identification of type of carbapenemase genes in clinical CRKp isolates. Clonal relatedness and sequence typing of CRKp isolates will be determined by using MLST (Multi-locus sequence typing) method. Both multiplex PCR and MLST will be performed in reference centres of each country.

8. Statistical Analysis:

In this study, the patients who develop BSI with CRKp vs. any bacteria vs. do not develop any infection will be matched in a 1:1:2 ratios by using relevant parameters. The same procedure will be applied for the patients who develop invasive infections without bacteremia. The variables are expressed as absolute numbers and their relative frequencies. Continuous variables are expressed as mean and SD if normally distributed, or as median and interquartile range (IQR) if non-normally distributed. Discrete variables for the matched pairs were compared by McNemar's test; for continuous variables we used the Wilcoxon test. All the variables being associated with CRKp BSI or other invasive infections in the crude analysis (p <0.1) were included in a backward, stepwise multivariate logistic regression model, separately. Overall goodness of fit for model will be analyzed by Akiake's Information Criteria (AIC) and Nagelkerke's R-square. Discrimination of the model will be assessed by receiver-operator curve (ROC) characteristics. Internal validation of final risk score model and decision tree algorithm will be made with last 1/3 enrolled patients of all cohort (validation cohort). The data of first 2/3 recruited patients will be used to develop risk score model and decision tree algorithm (derivation cohort). The risk of development of subsequent BSI wtih CRKp vs. any other bacteria vs. patients not having any type of infections through 90-days follow-up in CRKp colonized patients will be assessed by cox proportional hazards models in separate analyzes as well as the risk of development of other invasive infections in the same groups through 90-days follow-up will be analyzed by the same statistical method.

To develop the risk score, variables that maintain statistical significance in the multivariate regression model will be assigned a point value corresponding to the beta-coefficient divided by the lowest beta-coefficient identified in the regression model, and the resulting quotient will be multiplied by two and rounded to the nearest whole number. Summation of the points generated by the calculated risk factors will result in a quantitative score that will be assigned to each patient in the database. Optimal breakpoint will be assigned by the Youden's J statistic.

In summary, a decision tree will be built using the following steps: (1) identification of the most appropriate single variable that can divide the dataset into 2 groups ("nodes"), best minimized impurity of CRKp BSI or other invasive infections with CRKp status in each daughter node, according to the Gini impurity criterion, (2) repetition of the branching process within each daughter node and subsequent generations of nodes and (3) cessation at "terminal" nodes when no additional variables achieve further reductions in node impurity by applying pre-defined cut-off values for branching.

Study Type

Observational

Enrollment (Anticipated)

520

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

All adult (≥18 years) patients having rectal colonization or history of previous invasive infection with CRKp within previous 90 days of index invasive infection

Description

Inclusion Criteria:

  • All adult (≥18 years) patients having rectal colonization or history of previous invasive infection with CRKp
  • Group 1 cases are constituted by one BSI episode or non-bactereamic invasive infection episode (eg. pneumonia, intra-abdominal infection or urinary tract infection) with CRKp and a positive rectal swab screening or invasive infection (e.g. pneumonia, urinary tract infection and BSI) with CRKp within 90 days before identification of index BSI or other invasive infection with CRKp
  • Group 2 cases who are colonized with CRKp or had invasive infection (e.g. pneumonia, urinary tract infection and BSI) with CRKp within 90 days before identification of index BSI or other types of invasive infection with any bacteria other than CRKp and develop subsequent BSI or non-bactereamic invasive infection with these bacteria
  • Group 3 cases involve the colonized patients with CRKp who do not develop subsequent BSI or other invasive infections with CRKp or any other bacteria

Exclusion Criteria:

  • <18 years old patients
  • Palliative patients
  • Pregnant and breast-feeding patients
  • Patients who cannot be followed through 90-days.
  • Patients who are de-colonized with antibiotics, prebiotics-probiotics or fecal microbiota transplantation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Infection caused by CRKp
Group 1 cases are constituted by one BSI episode or non-bactereamic invasive infection episode (eg. pneumonia, intra-abdominal infection or urinary tract infection) with CRKp and a positive rectal swab screening or invasive infection (e.g. pneumonia, urinary tract infection and BSI) with CRKp within 90 days before identification of index BSI or other invasive infection with CRKp
Diagnostic test: Detection of CRKp colonization
Detection of CRKp colonization will be performed in all participants by sceening with rectal swab
Infection caused by any other bacteria
Group 2 cases who are colonized with CRKp or had invasive infection (e.g. pneumonia, urinary tract infection and BSI) with CRKp within 90 days before identification of index BSI or other types of invasive infection with any bacteria other than CRKp and develop subsequent BSI or non-bactereamic invasive infection with these bacteria
Diagnostic test: Detection of CRKp colonization
Detection of CRKp colonization will be performed in all participants by sceening with rectal swab
No infection
Group 3 cases involve the colonized patients with CRKp who do not develop subsequent BSI or other invasive infections with CRKp or any other bacteria
Diagnostic test: Detection of CRKp colonization
Detection of CRKp colonization will be performed in all participants by sceening with rectal swab

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The factors that are associated with the development of subsequent BSI or other types of invasive infection with CRKp in CRKp carriers.
Time Frame: 90-day
The independent risk factors (eg. presence of central venous catheter and presence of absolute neutropenia) for development of BSI or other invasive infections wtihin 90-days follow-up in CRKp carriers will be analyzed by constructing mutli-variate logistic regression analysis model.
90-day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Calculation of sensitivity and specificity rates, positive and negative predictive values of risk score model.
Time Frame: 90-day
These results will demonstrate better tool for our routine practices
90-day
Calculation of sensitivity and specificity rates, positive and negative predictive values of decision tree algorithm.
Time Frame: 90-days
These results will demonstrate better tool for our routine practices
90-days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

SCARE (Study group for carbapenem resistance)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ANTICIPATED)

April 1, 2020

Primary Completion (ANTICIPATED)

April 1, 2021

Study Completion (ANTICIPATED)

November 1, 2021

Study Registration Dates

First Submitted

January 4, 2020

First Submitted That Met QC Criteria

January 12, 2020

First Posted (ACTUAL)

January 18, 2020

Study Record Updates

Last Update Posted (ACTUAL)

January 18, 2020

Last Update Submitted That Met QC Criteria

January 12, 2020

Last Verified

January 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • DETERMINE301219

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Any data of participants will be shared with other investigators except the data of their patients

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Central Nervous System Infections

Clinical Trials on Detection of CRKp colonization

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe